Merck’s experimental drug efinopegdutide, which belongs to the GLP-1 class and is being developed as a treatment for non-alcoholic steatohepatitis (NASH), also showed a “compelling” weight-loss benefit.
Tag Archive for: non-alcoholic steatohepatitis
In a collaboration agreement announced today, Boehringer Ingelheim will gain access to Ribo’s platform to target hepatocytes with investigational siRNA therapies for non-alcoholic steatohepatitis.
Once a hot target for investors, the non-alcoholic steatohepatitis space has hit a succession of snags this year—so many that some analysts believe big pharma is no longer interested in taking the risk. This could make getting the first targeted therapies to the market tricky, but experts say the adjacent weight loss space offers a compelling opportunity.
Shares of Intercept Pharmaceuticals fell 16% on Monday over concerns about the prospects of the company’s drug to treat a type of fatty liver disease after the regulator’s advisory panel voted to defer an accelerated approval.
Altimmune released mid-stage data Tuesday showing pemvidutide helped reduce patients’ weight by 10%, but the company’s shares tumbled 55% over safety concerns with the obesity drug.
